TY - JOUR
T1 - Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT
T2 - results of the EBMT LWP
AU - López-Pereira, Patricia
AU - Bazarbachi, Ali
AU - Marçais, Ambroise
AU - Ngoya, Maud
AU - Khvedelidze, Irma
AU - Laurence, Arian
AU - Potter, Victoria
AU - Sicre de Fontbrune, Flore
AU - Tanase, Alina Daniela
AU - Cook, Lucy
AU - Chaganti, Sridhar
AU - Nicholson, Emma
AU - Serroukh, Yasmina
AU - Clay, Jennifer
AU - Labussière-Wallet, Hélène
AU - Ciceri, Fabio
AU - Glass, Bertram
AU - Hermine, Olivier
AU - Sureda Balari, Anna
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Limited 2026.
PY - 2026/1/3
Y1 - 2026/1/3
N2 - Adult T-cell leukemia/lymphoma (ATLL) is a rare HTLV-1-associated malignancy with a dismal prognosis due to intrinsic chemoresistance and immunosuppression. This retrospective EBMT registry analysis evaluated outcomes of allogeneic stem cell transplantation (allo-SCT) in 73 ATLL patients transplanted between 2004 and 2021. With a median follow-up of 3.9 years, 2-year overall survival (OS) and progression-free survival (PFS) were 49% (95% CI 37–60) and 43% (95% CI 31–54), respectively. Non-relapse mortality was 7% at 2 years, while relapse incidence (RI) was 49.8%. Multivariate analysis identified haploidentical donors as associated with improved OS, while non-CR status at transplant was independently associated with significantly worse PFS (HR 2.93, p = 0.01), OS (HR 4.12, p = 0.002), and RI (HR 2.66, p = 0.04) compared to CR. Our findings suggest that allo-SCT represents a feasible and potentially curative consolidation strategy for ATLL patients, with CR at transplant, younger age, and haploidentical donors being independent predictors of improved survival, supporting the importance of disease control, patient selection, and alternative donor strategies.
AB - Adult T-cell leukemia/lymphoma (ATLL) is a rare HTLV-1-associated malignancy with a dismal prognosis due to intrinsic chemoresistance and immunosuppression. This retrospective EBMT registry analysis evaluated outcomes of allogeneic stem cell transplantation (allo-SCT) in 73 ATLL patients transplanted between 2004 and 2021. With a median follow-up of 3.9 years, 2-year overall survival (OS) and progression-free survival (PFS) were 49% (95% CI 37–60) and 43% (95% CI 31–54), respectively. Non-relapse mortality was 7% at 2 years, while relapse incidence (RI) was 49.8%. Multivariate analysis identified haploidentical donors as associated with improved OS, while non-CR status at transplant was independently associated with significantly worse PFS (HR 2.93, p = 0.01), OS (HR 4.12, p = 0.002), and RI (HR 2.66, p = 0.04) compared to CR. Our findings suggest that allo-SCT represents a feasible and potentially curative consolidation strategy for ATLL patients, with CR at transplant, younger age, and haploidentical donors being independent predictors of improved survival, supporting the importance of disease control, patient selection, and alternative donor strategies.
UR - https://www.scopus.com/pages/publications/105026601712
U2 - 10.1038/s41409-025-02783-z
DO - 10.1038/s41409-025-02783-z
M3 - Article
C2 - 41486188
AN - SCOPUS:105026601712
SN - 0268-3369
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
ER -